Literature DB >> 1162569

Tumors of the liver as demonstrated by angiography, scan and laparotomy.

D K Kim, J McSweeney, S D Yeh, J G Fortner.   

Abstract

One hundred and eighteen patients with various hepatic tumors proved by laparotomy have been analyzed for accuracy and for pitfalls of preoperative studies, namely, physical examination, celiac and superior mesenteric angiography and liver scan. Angiography is correct in detecting a hepatic tumor in 93 per cent and scan, in 87 per cent, overall. When angiography and scan are combined, tumors are detected in 97 per cent of patients. As for specific location and extent of the hepatic tumor to determine its resectability, angiography is correct in 75 and scan in 62 per cent, over-all. Eleven of 39 resectable tumors were deemed nonresectable in preoperative studies. Although angiography and scan are the best available means of diagnosing hepatic tumors, presently, true resectabilty of hepatic tumors can be determined only be exploratory examination.

Entities:  

Mesh:

Year:  1975        PMID: 1162569

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  4 in total

1.  Benign hepatic lesions in women taking oral contraceptives.

Authors:  T J Davis; R N Berk
Journal:  Gastrointest Radiol       Date:  1977-12-20

2.  Resection and embolization in the management of secondary hepatic tumors.

Authors:  L H Blumgart; D J Allison
Journal:  World J Surg       Date:  1982-01       Impact factor: 3.352

3.  Multivariate analysis of a personal series of 247 patients with liver metastases from colorectal cancer. II. Treatment by intrahepatic chemotherapy.

Authors:  J G Fortner; J S Silva; E B Cox; R B Golbey; H Gallowitz; B J Maclean
Journal:  Ann Surg       Date:  1984-03       Impact factor: 12.969

4.  Measurement of high molecular weight forms of enzymes in serum in the detection of hepatic metastases of colorectal cancer.

Authors:  O J Traynor; C B Wood; Z O Echetebu; K B Whitaker; D W Moss
Journal:  Br J Cancer       Date:  1986-04       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.